News

Filter

Current filters:

RochePharmaceutical

1 to 9 of 612 results

Indian government caught unawares over flu pandemic

Indian government caught unawares over flu pandemic

09-03-2015

The recent outbreak of infections and death caused by the influenza A H1N1 strain across India has turned…

Anti-viralsGlaxoSmithKlineHealthcareIndiaMarkets & MarketingPharmaceuticalPoliticsRelenzaRocheTamiflu

Targeted lung cancer therapies supplanting conventional drugs; report

03-03-2015

Although lung cancer is the third most prevalent cancer type in the world, there are only 18 drugs in…

AstraZenecaBristol-Myers SquibbEli LillyMarkets & MarketingMerck & ConecitumumabOncologyOpdivoPharmaceuticalResearchRoche

FDA accepts and grants priority review for Genentech's cobimetinib/Zelboraf

FDA accepts and grants priority review for Genentech's cobimetinib/Zelboraf

20-02-2015

Genentech, part of the Roche Group, says that the US Food and Drug Administration has accepted and granted…

cobimetinibGenentechOncologyPharmaceuticalRegulationRocheUSA

Roche acquires Germany’s Signature Diagnostics

Roche acquires Germany’s Signature Diagnostics

10-02-2015

Swiss cancer drugs giant Roche has acquired Signature Diagnostics, a privately-held company based in…

Mergers & AcquisitionsOncologyPharmaceuticalRocheSignature Diagnostics

Roche announces positive Phase III results of Gazyva in non-Hodgkin's lymphoma

Roche announces positive Phase III results of Gazyva in non-Hodgkin's lymphoma

04-02-2015

Swiss drug major Roche has announced positive results from the Phase III study of Gazyva (obintuzumab)…

GazyvaOncologyPharmaceuticalResearchRoche

Chugai to expand Singapore R&D unit with $476 million investment

03-02-2015

Japan's Chugai Pharmaceutical, which is majority owned by Swiss pharma giant Roche, plans to invest $476…

Chugai PharmaceuticalFinancialPharmaceuticalResearchRocheSingapore

Roche's MPDL3280A granted FDA Breakthrough Therapy Designation in non-small cell lung cancer

Roche's MPDL3280A granted FDA Breakthrough Therapy Designation in non-small cell lung cancer

02-02-2015

The US Food and Drug Administration has granted Breakthrough Therapy Designation for MPDL3280A (anti-PDL1)…

Lung cancerMPDL3280ANon-small cell lung cancerNon-small-cell lung carcinomaOncologyPharmaceuticalRegulationRocheUSA

Roche’s 2014 profits miss forecasts, impacted by costs

Roche’s 2014 profits miss forecasts, impacted by costs

28-01-2015

Despite posting higher sales for full-year 2014, Swiss pharma major Roche missed analysts’ forecasts,…

FinancialPharmaceuticalReutersRocheUnited States

1 to 9 of 612 results

Back to top